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Th2 cytokinesAbstract In contrast to mice, rats are less-susceptible to infection with Schistosoma mansoni, per-
haps mounting protective immune responses that provide a microenvironment unfavorable for the
normal growth and survival of the parasite. Upon infection, schistosomular excretory–secretory
products (ESP) trigger T helper (Th) effector cells and polarize the immune microenvironment.
We investigated the differences in mouse and rat immune responses to the larval ESP, 14-3-3-like
protein, P18, and fructose-1,6-bisphosphate aldolase, prepared in a recombinant or multiple antigen
peptide form. Ex vivo spleen cells (SC) of naı¨ve, and 7 day-S. mansoni-infected CD1 mice and
Wistar rats were stimulated in vitro with the selected ESP, and the culture supernatants were
assessed for cytokine levels by capture enzyme-linked immunosorbent assay. S. mansoni ESP failed
to induce SC of 7 day-infected mice to produce detectable interleukin (IL)-4 levels, but led to sig-
niﬁcant increase in released interferon-gamma (IFN-c) as compared to naı¨ve mice. Conversely,
SC of rats released signiﬁcant IL-4 levels in response to ESP stimulation, while IFN-c was hardly
detected in the supernatants. Amounts of ESP-speciﬁc antibodies in infected rats were signiﬁcantly
higher than in infected mice. Our results suggest that resistance to schistosomiasis is associated with
type 2 cytokines and high levels of parasite ESP-speciﬁc antibodies.
ª 2015 The Egyptian German Society for Zoology. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Schistosomiasis is a major, severe, yet neglected tropical hel-
minthic disease. It affects 207 million people in the developing
world with approximately 800 million, mostly children, at risk
of the infection (King, 2010, 2015; Siddiqui et al., 2011). No
vaccine is available as yet. The T helper (Th)1 and Th2 para-
digms have been redrawn with the discovery that the third
effector Th17 CD+4 subset is playing important roles in the
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et al., 2005; Harrington et al., 2006; Bi et al., 2007; Shainheit
et al., 2008; Tallima et al., 2009; Rutitzky and Stadecker,
2011). For many parasites, protection has been associated with
either Th1- Th2- or Th17 type cytokine production. In helmin-
thic infection, Th1, Th2, and Th17 cytokine microenvironment
inﬂuences the immune response to the parasites (Diaz and
Allen, 2007; Allen and Maizels, 2011; Bourke et al., 2013).
In humans, the immune response to invading schistosomes
is predominantly of the Th1 inﬂammatory type, with high lev-
els of tumor necrosis factor-a, interleukin (IL)-1, IL-6 and
interferon (IFN)-c characterizing the acute phase of schistoso-
miasis (de Jesus et al., 2002; Caldas et al., 2008; Reis et al.,
2008). However, the chronic phase of the disease is character-
ized by predominance of the Th2 immune responses to egg
antigens, low levels of IFN-c, and high production of IL-4,
IL-5, IL-13, and IL-10 (Williams et al., 1994; Yu et al.,
2012). Importantly, within schistosomiasis-endemic areas,
resistance to reinfection after speciﬁc chemotherapy has been
correlated with Th2 immune responses, with the presence of
speciﬁc IgE (Black et al., 2010; Figueiredo et al., 2012;
Fitzsimmons et al., 2012) and production of IL-4 and IL-5
(Joseph et al., 2004; Ganley-Leal et al., 2006).
After infection with cercariae under laboratory conditions,
the developmental rate of Schistosoma (S.) mansoni and japon-
icum in mice and rats was nearly 65% and 15%, respectively
(Jiang et al., 2010). In rats, S. mansoni infection is character-
ized by higher death rate of schistosomula in skin and fewer
schistosomula migrations toward the portal system than mice,
and worms fail to migrate from the liver portal circulation into
mesenteric veins. In rats, only a small percentage of infective
cercariae reach the adult stage and the rate of egg laying is very
low (Silva-Leita˜o et al., 2009). The mouse is reported to be a
deﬁnitive permissive host, in contrast to the rat, which is
semi-permissive (less susceptible) (Cioli et al., 1977). This dif-
ferential susceptibility might be attributed to the host primary
immune responses to the invading larvae, especially in the
lung, known as the major site of innate and adaptive immu-
nity-mediated attrition of schistosomes (Dean and Mangold,
1992; Coulson, 1997).
Murine immune response to migrating schistosomula is
characterized by the production of Th1 and Th17 cytokines,
and limited amounts of antibodies (Pemberton et al., 1991;
Mountford et al., 1995; El Ridi et al., 2006a,b, 2010; Tallima
et al., 2009; El Ridi et al., 2010). Conversely, schistosome infec-
tion was shown to drive Th2 responses in rats, with preponder-
ance of IL-4 and IL-5 and lack of IFN-c production (Ceˆtre
et al., 1998, 1999; Khalife et al., 2000). The role of Th2 cyto-
kines in resistance to schistosome infection was, thus, reported
to be operational in rats as in humans (Ceˆtre et al., 1999). On
the other hand, the dominant dogma is that induction of pro-
tective immunity against murine schistosomiasis is dependent
on a polarized Th1 environment (Coulson, 1997; Siddiqui
et al., 2011; Zhang et al., 2011), despite that S. mansoni infec-
tion vigorously proceeds ahead amid powerful Th1 and Th17-
associated immune responses.
Strategies for schistosomiasis control programs are unable
to eradicate the infection and the development of a vaccine
is an urgent demand. However, a vaccine that elicits more than
partial protection against infection has not yet been developed
(Bergquist et al., 2008; El Ridi and Tallima, 2013a; Othman
and El Ridi, 2014). Parasite cytosolic and surface membraneantigens are entirely inaccessible to the effective elements of
the host immune responses; yet, larval excretory–secretory
products (ESP) are readily presented to the host lymphocytes,
induce effector cells and speciﬁc antibody-producing lympho-
cytes and are accessible targets to the diverse immune effectors
(El Ridi and Tallima, 2009; El Ridi et al., 2010). Numerous S.
mansoni larval ESP, among many others glutathione-S-trans-
ferase (Balloul et al., 1987; McManus, 1999), triose-phosphate
isomerase (Reis et al., 2008), glyceraldehyde-3 phosphate dehy-
drogenase, SG3PDH (El Ridi et al., 2001), calpain (Siddiqui
et al., 2011; Zhang et al., 2011), 2-Cys-peroxiredoxin
(Donnelly et al., 2008) and 14-3-3-like protein (El Ridi and
Tallima, 2009; El Ridi et al., 2010) have been identiﬁed, cloned,
expressed and found to be highly immunogenic in man and
mouse, essentially inducing Th1- and Th17-related immune
responses. We have used some of these molecules, in a recom-
binant or multiple antigen peptide (MAP) construct, to com-
pare the S. mansoni infection-induced primary immune
responses in permissive (mice) and semi-permissive (rats) labo-
ratory hosts.
Comparing immune responses between permissive and
semi-permissive animal models could provide an important
approach toward knowledge of the favorable environment
for deﬁning a potential immunological milieu for resistance
to schistosomes. In the present design, outbred rats and mice
were examined in parallel for the ﬁrst time for analysis of
the levels of antibody response and the ESP-induced cytokine
types released by ex vivo spleen cells (SC) of naı¨ve and 7 day
S. mansoni-infected hosts.Materials and methods
Animals and cercariae
Outbred female, 20–22 g CD1 mice were purchased from the
Schistosome Biological Materials Supply Program, Theodore
Bilharz Research Institute (SBSP/TBRI), Giza, Egypt. Out-
bred female Wistar rats weighing 48–52 g were obtained from
the National Research Institute, Giza, Egypt. All animal
experiments were performed following the recommendations
of the current edition of the Guide for the Care and Use of
Laboratory Animals, Institute of Laboratory Animal
Resources, National Research Council, USA. Cercariae of
an Egyptian strain of S. mansoni were obtained from SBSP/
TBRI and used for infection immediately after shedding from
Biomphalaria alexandrina snails.
Animal infections
For each of 2 separate experiments, mice and rats were divided
into four groups: naı¨ve mice (control M; n= 6), naı¨ve rats
(control R; n= 6), infected mice (infected M; n= 6), and
infected rats (infected R; n= 6). Infection was performed per-
cutaneously, via whole body exposure, with 200 ± 25 cerca-
riae for mice and 400 ± 25 cercariae for rats. The number of
cercariae was deemed appropriate considering the average
weight of the hosts. Naı¨ve and infected animals were bled
and sacriﬁced 7 days after infection. This time point was
selected as it corresponds to the approximate time when invad-
ing larvae reach the lung, documented as the major site of par-
asite attrition (Dean and Mangold, 1992; Coulson, 1997).
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Puriﬁed recombinant lung-stage ESP vaccine antigens included
S. mansoni 14-3-3 like-protein and P18 (El Ridi and Tallima,
2009). cDNA clone encoding P18 antigen was expressed using
Champion pET SUMO Protein Expression Kit. The product
of 12 kDa fused to a 13 kDa vector-derived tag and SUMO
protein was detected in the soluble compartment of induced
bacteria, and puriﬁed by nickel afﬁnity chromatography.
Recombinant (r) 14-3-3-like protein was puriﬁed to homogene-
ity as described (El Ridi et al., 2001; El Ridi and Tallima, 2009)
and contained, 0.06 endotoxin units per milliliter as judged
by the Pyrogen Gel-Clot Limulus Amebocyte Lysate (LAL)
Test Method (Lonza, Walkersville, Maryland). A peptide
selected from S. mansoni fructose 1, 6 biphosphate aldolase
[(El-Dabaa et al., 1998)-SmAld: H-340VGKFEGNMGTT
LGDKSLFV358-OH] (El Ridi and Tallima, 2009; El Ridi
et al., 2010) was constructed as a tetra branched multiple
antigen peptide construct (ALD MAP) and puriﬁed at
AnaSpec, Inc. (San Jose, California).
Spleen cell cultures
Spleens were removed from each mouse and rat in all groups
for cell suspension preparation. Spleens were squeezed
through a ﬁne wire mesh and splenic erythrocytes were lysed
by osmotic treatment (0.017% M Tris-buffered saline, 0.16%
M ammonium chloride solution, pH 8.0), followed by three
washes in RPMI 1640 (Gibco BRL, USA). Cell viability
was evaluated by trypan blue dye exclusion, and cells were
suspended in culture medium, which is RPMI 1640 supple-
mented with 10% heat-inactivated fetal calf serum (FCS,
Bio whittaker, Verviers, Belgium), 100 U/ml penicillin,
50 lg/ml of gentamicin (GibcoBRL), 2 mM L-glutamine
(Gibco BRL), 1 mM sodium pyruvate (Gibco BRL, USA),
and 5 · 105 M 2-mercaptoethanol (ICN, Costa Mesa, CA),
100 lg/ml streptomycin, 25 mM HEPES, 50 ng/ml amphoter-
icin, 15 lg/ml polymyxin B (Sigma, Chemical Company, St,
Louis, MO) as inhibitor of any residual lipopolysaccharide
contamination of recombinant antigens (Cardoso et al.,
2007). Splenocytes were cultured at a concentration of
1 · 106 cells/well in duplicate wells of 3 parallel 96 well plates
(Coaster, USA), incubated with 50 lg/ml membrane ﬁlter
(0.45 mm) sterilized r14-3-3-like protein, P18 or ALD MAP
at 37 C under 5% CO2 atmosphere. Supernatants were col-
lected after 48 h for IL-4 and after 96 h for IL-17 and IFN-c
measurement (El Ridi et al., 2010) and maintained at 80 C
until use.
Cytokine analysis
Levels of mice cytokines (IL-4, IL-17 and IFN-c) were assessed
by capture enzyme-linked immunosorbent assay (ELISA)
(ELISA MAX Set, BioLegend, Inc., San Diego, CA,
USA). For rats, IL-4 was estimated by DuoSet ELISA Devel-
opment System (R&D Systems Europe, Abingdon, United
Kingdom), IL-17 by ELISA MAX Deluxe Set (BioLegend)
and IFN-c by Quanti kine ELISA (R&D Systems Europe).
Capture ELISA was performed following the manufacturer’s
instructions.Serum preparation and humoral responses
Sera were obtained from naı¨ve animals and infected mice and
rats at 7 days following infection with cercariae of S. mansoni.
Indirect ELISA was applied to detect the levels of speciﬁc anti-
bodies in the sera of animals. Wells of polystyrene 96 plates
(Costar, Cambridge, MA) were coated with 0.25 lg r14-3-3,
0.025 lg P18, or 2 lg ALD MAPs in 100 ll carbonate/bicar-
bonate buffer, pH 9.6 per well at 4 C overnight. After washing
three times with phosphate-buffered saline (PBS)/0.05%
Tween 20 (washing buffer), the wells were blocked with 1%
bovine serum albumin (Win Lab., UK) in 0.05 M PBS, pH
7.1 and incubated for 75 min. After washing ﬁve times, sera
serially diluted in washing buffer (1:100, 1:200, 1:400 and
1:800) and 100 ll added to duplicate wells at 37 C for 1 h.
After washing ﬁve times, goat anti-mouse/rat IgG (H+L) con-
jugated to horseradish peroxidase (Promega, Madison, Wis-
consin, USA) and peroxidase (KPL, Gaithersburg, USA),
respectively, diluted 1:3000 and 1:2000, respectively in washing
buffer and 100 ll added to wells at 37 C for 1 h. After wash-
ing ﬁve times, 100 ll of ABTS [2-2-azinobis (3-ethylbenzo-
thiazoline-6-sulfonic acid)-diammonium salt] substrate
(Pierce, Rockford, USA), were added to all wells. Optical den-
sities (OD) were estimated spectrophotometrically at 405 nm.
Sera giving mean values higher than the cut off value [mean
of the serum from naı¨ve uninfected mice or rat +2 standard
error (SE)] were considered positive.
Statistical analysis
Data are expressed as mean ± standard error of mean (SEM).
Independent Student’s ‘‘t’’ tests were used to determine the sta-
tistical signiﬁcance differences between infected groups and
control values. P> 0.05 is insigniﬁcant, while P< 0.05 is sig-
niﬁcant at a= 0.05.
Results
Cytokine response of ESP-stimulated spleen cells
The cytokine proﬁle pattern of ex vivo SC in response to stim-
ulation with lung larval ESP was evaluated in mice and rats.
SC from naı¨ve and 7 day infected CD1 mice failed to release
detectable levels of IL-4 after 48 h in vitro stimulation with
r14-3-3-like protein, rP18 or ALDMAP (Fig. 1A). Conversely,
SC from naı¨ve and 7 day infected rats produced detectable
IL-4 levels in culture supernatants after ESP stimulation.
Of note, stimulation of ex vivo SC for 48 h with ALD MAP
triggered signiﬁcant (P< 0.01) increase of IL-4 compared to
naı¨ve rats, whereas r14-3-3-like protein and rP18 stimulated
increase in the levels of IL-4 in culture supernatants SC of
infected rats but the changes did not reach signiﬁcance
comparing to naı¨ve rats (Fig. 1B).
Infection of mice with S. mansoni triggered Th1 immune
responses as judged by signiﬁcant (P< 0.05) release of IFN-
c in SC culture supernatants stimulated with rP18 and ALD
MAP in regard to naı¨ve mice (Fig. 1C). Recombinant 14-3-
3-like protein induced signiﬁcantly (P< 0.01) higher amounts
of IFN-c in culture supernatants of mice SC compared to
naı¨ve mice. On the other side, Th1 immune responses are
Figure 1 Th1 (IFN-c), Th2 (IL-4), and Th17 (IL-17) responses elicited by lung schistosomula excretory–secretory products (ESP) in
recombinant or MAP form, in ex vivo spleen cells (SC) of CD1 mice and Wistar rats, assessed 7 day post-infection with S. mansoni
cercariae. Ex vivo SC cultures were stimulated with recombinant (r) 14-3-3-like protein, rP18 and ALD MAP. Cytokine levels were
assayed after 48 h for IL-4 (A, B) and 96 h for both IFN-c (C, D) and IL-17 (E, F) in SC culture supernatants by capture ELISA.
Columns represent mean levels of cytokines in duplicate measurements for each group. Vertical bars depict standard error of the mean
(SE). Asterisks indicated a signiﬁcantly higher level as compared to its naı¨ve group (*P< 0.05, **P< 0.01, ***P< 0.001), ND: not
detected.
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detectable levels of IFN-c in stimulated SC in vitro cultures
of naı¨ve and 7 day infected rats. Recombinant 14-3-3-like pro-
tein induced non-signiﬁcant levels of IFN-c in SC of infected
rats as compared to naı¨ve rats (Fig. 1D).
With respect to Th17 responses, rP18 protein consistently
induced release of highly signiﬁcant (P< 0.001) IL-17 levels
in 96 h cultures of SC from 7 day infected mice compared to
SC of naı¨ve mice stimulated in parallel. Recombinant 14-3-3-
like protein and ALD MAP stimulated SC from 7 day infected
mice to release signiﬁcantly (P< 0.05) lesser amounts of IL-17
after 96 h in vitro stimulation than rP18 (Fig. 1E). Th17
cytokine response in rat SC supernatant cultures stimulatedwith r14-3-3-like protein, rP18 or ALD MAP were associated
with lower IL-17 levels than7 day infected mice, and their lev-
els did not signiﬁcantly change compared to SC cultures of
naı¨ve rats (Fig. 1F).
Humoral immune responses to ESP
In order to demonstrate the difference in immune responses
between rats and mice at the day 7 following infection with
cercariae of S. mansoni, sera were obtained from naı¨ve (non-
infected) and 7 day S. mansoni infected mice and rats. Sera
were then analyzed by ELISA for total speciﬁc antibodies
binding to ESP proteins produced in a recombinant or MAP
30 A.M. Badr et al.form. The immune total antibody responses with descending
reciprocal dilution for 2 repeat experiments including each 6
outbred CD1 mice and 6 Wistar rats are presented in Fig. 2.
All 7 day infected mice and rat sera had detectable levels of
antibodies against the different antigens used.
In infected mice, the humoral response during early S. man-
soni against the used three antigens was accompanied with
release of minimal amounts of total antibodies binding to
r14-3-3-like protein with absorbance of 0.077–0.02 for serum
dilutions of 1:100 and 1:800, respectively (Fig. 2A), while
infected rats in parallel showed release of higher amounts with
absorbance ranging from 0.32 to 0.153 (Fig. 2B). For rP18,
mouse sera showed absorbance levels ranging from 0.162 to
0.005 (Fig. 2C), whereas rats vigorously responded with absor-
bance of 0.553–0.072 at 1:100 and 1:800, respectivelyFigure 2 Antibody binding of sera from S. mansoni infected mice a
Typical data of 2 repeated experiments for mice and rats are shown. Ea
ELISA, of serum antibodies bound to r14-3-3-like protein (A, B), rP18
antibodies of 7 day infected hosts minus mean absorbance of serum f
antibody binding to r14-3-3-like protein, rP18 and ALDMAP. Bars ar
rats with standard error of the mean (SE). Asterisks show signiﬁcant d
infected rats compared to infected mice.(Fig. 2D). Additionally, the antibody levels binding to ALD
MAP ranged according to titer from 0.135 to 0.016; 0.366 to
0.076 for mice and rats, respectively (Fig. 2E, F). In 2 repeat
experiments, serum antibody levels to r14-3-3-like protein,
rP18, and ALD MAP at day 7 post infection were signiﬁcantly
(P< 0.001, P< 0.01, P< 0.01, respectively) higher in rats
than mice, with the highest humoral immune response directed
to rP18 (Fig. 2G).Discussion
S. mansoni larvae journey to reach the lungs within 4–6 days
(Rheinberg et al., 1998), and negotiate the lung capillaries
toward the liver, never to exit the blood vessels and capillaries.nd rats to lung schistosomula ESP in recombinant or MAP form.
ch point represents mean delta absorbance, as assessed by indirect
(C, D) and ALDMAP (E, F). Delta = mean absorbance of serum
rom naı¨ve hosts. (G) Serum antibody (1:100-diluted) responses of
e mean delta absorbance of speciﬁc antibodies of infected mice and
ifferences (*P< 0.01 and **P< 0.001) of antibody generation in
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products, likely access macrophages, dendritic cells, and B cells
in spleen rather than the lung tissue draining lymph nodes (El
Ridi et al., 2010). The survival and development of schistosom-
ula may be inﬂuenced by host response through host-parasite
interaction (Knopf et al., 1977; Silva-Leita˜o et al., 2009), and
migrating larvae are documented to be most vulnerable while
in the lung (Dean and Mangold, 1992; Coulson, 1997; El
Ridi and Tallima, 2013a). Hence, the day 7 post cercarial infec-
tion was our concern. We herein explored the immune
response during the critical lung larval stage of schistosomiasis
infection, holding a parallel comparison between mouse as sus-
ceptible host and naturally less-susceptible rat for infection
with schistosomiasis. The in vitro assays used here aimed at
screening Th1, Th2 and Th17 responses and levels of serum
antibodies relating them to susceptibility to schistosomiasis
infection in two types of rodent hosts.
For better assessing the correlation between cytokine bal-
ance and the resistance to S. mansoni infection in outbred
CD1 mice and Wistar rats, we analyzed the Th1, Th2, and
Th17 environment of ex vivo SC obtained from naı¨ve and
7 day S. mansoni infected hosts and cultured in the presence
of lung larval ESP of S. mansoni prepared in recombinant or
MAP form. Cytokine responses of SC recovered from entirely
naı¨ve hosts was found to be characterized by the ability to eli-
cit IL-17 and IFN-c production in murine SC cultures. Results
were entirely in concord with those obtained previously with
ESP-stimulated SC of inbred BALB/c and C57BL/6 mice (El
Ridi et al., 2010). Yet, they are the ﬁrst to show that those
schistosome molecules elicit in SC cultures of naı¨ve rats detect-
able amounts of IL-17 and IL-4, and almost no IFN-c. The
molecular basis of the difference in mouse and rat SC response
to the same molecules under the same conditions is unclear. It
might be ascribed to different interaction with, and antigen
presentation by, antigen presenting cells, and different activa-
tion signals for lymphocytes in the SC cultures for the 2 rodent
hosts. These ﬁndings help to predict that schistosomes invad-
ing rats are met with type 2 cytokines upon development and
migration, resulting soon into their attrition. We have recently
shown that S. mansoni infection of outbred mice, 1 h after
injection with papain, a cysteine protease known to generate
type 2 cytokines, led to reduction of more than 50% in worm
burden, compared to uninjected mice (El Ridi and Tallima,
2013a). Additionally, we have suggested that S. mansoni would
succumb in mice too if met, like in rats, with a polarized type 2
environment.
As for SC of naı¨ve mice, SC of mice exposed for 7 days to
migrating larvae produced IL-17 and IFN-c in mice in
response to the larval ESP whether in a recombinant or
MAP form. The results are entirely in concord with the type
of cytokine mRNA of peripheral blood mononuclear cells of
10–11 day S. mansoni-infected inbred BALB/c and C57BL/6
and outbred CD1 mice (El Ridi et al., 2006a,b). Rats SC
released IL-17 and IL-4 in rats in response to the larval ESP.
This is expected because ESP trigger immune microenviron-
ment polarization. IFN-c is known to induce the differentia-
tion of lymphocytes into Th1-type cells and inhibits the
development of Th2 cells while IL-4 promotes lymphocyte dif-
ferentiation into Th2-type cells and inhibits the development
toward the Th1 axis (Murphy and Reiner, 2002). Primary
and secondary immune responses to the test ESP are thus
dominated by type 1 and type 2 cytokines in mice and rats,associated with susceptibility and semi-permissiveness, respec-
tively. Resistance to schistosome infection was also found to be
associated with type 2 immune responses in baboons (Nyindo
et al., 1999), rhesus monkeys (Fallon et al., 2003), and humans
(Dunne et al., 1992; Fallon et al., 2003; Dessein et al., 2004;
Joseph et al., 2004; Ganley-Leal et al., 2006; Black et al.,
2010; Figueiredo et al., 2012; Fitzsimmons et al., 2012).
The results have pointed to another association between
permissiveness and semi-permissiveness in mice and rats,
respectively, and that is the level of schistosome-speciﬁc anti-
bodies generated during the ﬁrst week of infection, before
the larvae leave the lung and become entirely refractory to
any mechanism of immune attrition (Keating et al., 2006).
Indeed, the levels of murine antibodies binding to larval ESP
in a recombinant or MAP form were limited. These ﬁndings
fully corroborate earlier results documenting the negligible lev-
els of speciﬁc antibodies to parasite tegumental antigens (El
Ridi et al., 2006a,b) and ESP (El Ridi et al., 2010) in S. man-
soni-infected inbred and outbred mice, tested 7–10 days after
infection. Rats examined in parallel produced signiﬁcantly
higher levels of ESP antibodies. A higher level of serum anti-
bodies would facilitate interaction with ESP released in the
vicinity of intact larvae, increasing the probability of their
attrition. This contention is supported by reports showing that
rat’s resistance and rejection with subsequent re-challenge with
schistosome infection is associated with antibody effectors
(Horta and Ramalho-Pinto, 1984; Ceˆtre et al., 1999).
The results taken together indicated that semi-permissive-
ness in rats is associated with infecting larvae generating
type 2 cytokines and high levels of larval ESP-speciﬁc anti-
bodies, while full permissiveness in mice is associated with
infecting schistosomula generating type 1 cytokines and
low levels of larva ESP-speciﬁc antibodies. We have recently
shown that ESP in a recombinant or multiple antigen in
conjunction with type 2 cytokines inducing cytokines or
molecules consistently and reproducibly induced a highly
signiﬁcant (P< 0.0001) reduction of > 66% in challenge
S. mansoni worm burden and worm egg load in the liver
and the small intestine of outbred CD1 mice (El Ridi and
Tallima 2013b; El Ridi et al., 2014), thus providing strong
evidence in support of our advocate that an effective
schistosomiasis vaccine should predominantly evoke type 2
immune responses.Acknowledgments
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